profit from every $100 of sales.
$0$100
IO Biotech
We have no price for IO Biotech since 5 June 2026. It may have been taken over, merged or renamed, so the figures below are from then.
$0.01+26.15% today
-99.5% since Oct 7, 25
1-year low $0.011-year high $3.51
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What IO Biotech sold, what it kept, and what it did with the cash.
Sales went from $0 in 2021 to $0 in 2024, with -$95.5 million of profit last year.
SalesProfit
IO Biotech vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| IO Biotech | No profit yet | ||
 Vertex Pharmaceuticals | 35.1× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 21.0× · Fair price | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads IO Biotech's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| – | – | – | – | |
| -41 | -71 | -91 | -95 | |
| -67 | -69 | -91 | -94 | |
| -68 | -71 | -86 | -95 | |
| -17.30 | -2.48 | -1.98 | -1.45 | |
| – | – | – | – | |
| – | – | – | – | |
| – | – | – | – |
Balance sheet
| In millions of USD | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Total assets | 222 | 152 | 151 | 68 |
| Cash | 212 | 143 | 143 | 60 |
| Total debt | 0 | 3 | 2 | 2 |
| Total liabilities | 10 | 13 | 18 | 21 |
| 212 | 139 | 133 | 47 | |
| 4 | 29 | 44 | 66 | |
| -25.1% | -39.0% | -53.3% | -153.7% | |
| -32.0% | -51.5% | -64.6% | -203.1% |
Cash flow
| In millions of USD | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| -41 | -60 | -72 | -82 | |
| 0 | 1 | 0 | 0 | |
| -41 | -60 | -72 | -82 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 2 | 7 | 8 | 7 |
Valuation
- –
- –
- –
- 0.9×
- –
- –
- 0.3×
- -9,302.5%
- -10,781.5%
- 0.0%
Profitability
- 0.0%
- 0.0%
- 0.0%
- 0.0%
- -406.0%
- -160.7%
- -465.4%
- -221.1%
- -425.3%
- –
Growth
- –
- –
- −14.3%
- –
- +54.5%
Financial health
- 0.3×
- 1.60
- 3.6%
- -80.8×
- 2.01
- 2.01
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 21%of 870
What analysts expect
- Average price target
- $0.50
- Range
- $0.50 – $0.50
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Nov 14, 2025 | -0.28 | -0.31 | +9.7% |
| Aug 14, 2025 | -0.40 | -0.35 | −14.3% |
| May 14, 2025 | -0.34 | -0.45 | +24.4% |
| Mar 25, 2025 | -0.48 | -0.38 | −25.2% |
| Nov 12, 2024 | -0.36 | -0.29 | −24.1% |
| Aug 13, 2024 | -0.31 | -0.34 | +8.8% |
| May 14, 2024 | -0.30 | -0.37 | +18.9% |
| Mar 5, 2024 | -0.40 | -0.36 | −11.1% |
News
The Top 5 Biotech Stocks I'd Buy Right Now Without Any HesitationYahoo Finance · Nov 8, 2026Cathie Wood-Led Ark Loads Up On GOOG, AMD, NVDA And Biotech Stocks — But Sells CRWV, AVGO, LLYYahoo Finance · Nov 7, 2026Stock Market Today: Dow Dips On Election Day; These Biotech, Insurance Stocks Clear Entries (Live Coverage)Yahoo Finance · Nov 3, 20261 Dividend-Paying Biotech Stock to Buy Hand Over Fist in NovemberYahoo Finance · Nov 1, 20265 Best Biotech Stocks Under $10 to BuyYahoo Finance · Oct 31, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
38No pass
Benjamin Graham
53No pass
Philip Fisher
33No pass
Peter Lynch
33No pass
Joel Greenblatt
100Pass
Charlie Munger
23No pass
Terry Smith
26No pass
Questions about IO Biotech
Is IO Biotech a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the IO Biotech AI analysis
What does IO Biotech do?
IO Biotech, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating immune-modulating cancer treatments. These therapies leverage its proprietary T-win technology platform. It is in Biotechnology.
Does IO Biotech pay a dividend?
No. IO Biotech does not pay a dividend at the moment.
Is IO Biotech stock halal?
No. IO Biotech does not pass our halal screen: its debt is 216% of its market value, at or above the 33% limit. How we check
Who are IO Biotech's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with IO Biotech's.
Prices: daily closes to Jun 5, 2026. Fundamentals: company reports via invest-like data.